Martin Low has founded or co-founded eight companies including Eradivir, Inc., where he has been CEO since inception in March of 2020.  Prior to Eradivir, Inc., he served as CEO for 9 years at On Target Labs, another biotech he co-founded.  Under his leadership two drugs were brought into the clinic with the lead drug successfully filed with the FDA for approval in ovarian cancer. Throughout his career he has been successful in raising funds and securing partnerships.  For On Target, he raised $90M and secured partnerships with several key Medtech companies.  Martin has introduced several products that have won awards from Business Week, The Thomas Edison Foundation and the Smithsonian Institute. Martin has degrees from Purdue University and Northwestern’s Kellogg Graduate School of Management.

Dr. Ashley Wozniak is Chief Operating Officer at Eradivir, Inc and brings nearly 20 years of biotechnology industry experience spanning research and development, product development, commercialization, government partnerships, and executive leadership.

Prior to joining Eradivir, Inc, Dr. Wozniak held multiple leadership positions at Emergent BioSolutions, including General Manager and Vice President of Government Business, where she led global teams responsible for commercial and government-funded product portfolios distributed in more than 30 countries. She is also the founder of Fosera Consulting, where she has advised biotechnology and healthcare companies on corporate strategy, business development, commercialization, operations, and organizational growth. Throughout her career, she has led cross-functional organizations supporting the development, approval, commercialization, and lifecycle management of critical medical products and has managed strategic partnerships and government-funded programs focused on public health preparedness, biodefense, and medical countermeasures.

As Chief Operating Officer, Dr. Wozniak oversees Eradivir, Inc’s clinical development, chemistry, manufacturing and controls (CMC), regulatory affairs, and operational functions.

Dr. Wozniak earned a B.Sc. in Chemistry from the University of Winnipeg and a Ph.D. in Molecular Biology from the University of Manitoba.

Dr. Neilsen is Chief Science Officer at Eradivir, Inc., overseeing the early discovery and preclinical development efforts for the pipeline of Eradivir, Inc. He has spent the last 12 years on early drug discovery and development. He is trained both as a chemist and a biologist using an interdisciplinary approach to design and discover next generation targeted therapeutics. Dr. Nielsen has successfully led R&D teams in academia at Brigham Young University, Max Planck Institute, and Purdue University and in industry at Biofire diagnostics, Novosteo and Quince therapeutics. Dr. Nielsen was part of an integral team that led to the translation of technology for Novosteo from discovery to acquisition by the publicly traded company Cortexyme. Two products he was part of the discovery team for are now FDA approved and marketed. Dr Nielsen has founded or co-founded 4 successful companies in 2 different industries.   He has published 27 peer reviewed journal articles and abstracts and is a primary inventor on 35 US and international patents/patents pending. Dr Nielsen has additionally presented at over 50 international and national scientific conferences and been awarded 38 academic and professional awards including the young investigator award from the American Society of Bone and Mineral Research. He earned a B.S. in Biochemistry and B.S. in Genetics and Biotechnology with a concentration in human disease from Brigham Young University and a PhD in Medicinal Chemistry and Molecular Pharmacology from Purdue University.

Aaron has been involved in clinical research since 2002, having worked his way up from research assistant to program manager in academia before pivoting to industry in 2014. He comes to Eradivir, Inc. with a wealth of experience in operationalizing clinical trials, ranging from investigator-initiated pilot studies through global Phase 3 clinical programs (and everything in-between) at start-ups and big pharma. An alumnus of the University of Pennsylvania and La Salle University, he is proud to have notched several successful NDAs and spends his free time pretending to be a musician.

Gerald Artman is a seasoned pharmaceutical leader with a proven track record of advancing small molecule therapies from pre-IND through commercial launch. With extensive experience at both large pharmaceutical organizations (Novartis, Celgene/Bristol Myers Squibb, GSK) and innovative biotechs (Bellus Health, Reata Pharmaceuticals, Sionna Therapeutics), Jerry has served as a cross-functional CMC subject matter expert, designing patentable, scalable, and cost-effective manufacturing processes across all clinical phases.

At Reata Pharmaceuticals, Gerald led CMC strategy as the primary R&D, manufacturing, and authoring SME, culminating in the submission of two NDAs—including the successful approval of Skyclarys™ (omaveloxolone), the first and only FDA-approved treatment for Friedreich’s ataxia (2023, Reata/Biogen). He also played a pivotal role in the $2 billion acquisition of Bellus Health by GSK, recognized as a key CMC contributor during due diligence for the Phase 3 asset camlipixant.

Gerald excels in global CDMO leadership, overseeing operations across Asia, Europe, and North America while navigating time zones, cultural dynamics, and regulatory shifts—including the BioSecure Act and evolving U.S. tariff policies. He has built a robust, geographically diverse network of trusted manufacturing partners to ensure supply chain resilience for APIs, key materials, and drug products.

Driven by a passion to deliver life-changing therapies to patients in need, Gerald combines scientific rigor, operational discipline, and strategic foresight to accelerate development and secure long-term success.